Press release from Companies
Publicerat: 2025-06-30 07:43:54
SensoDetect AB, a pioneer in neuropsychiatric screening and diagnostic support, today announced promising interim results from its clinical ASD study in Saudi Arabia.
Interim Findings: Validation of Method and AI Performance
"The initial data confirms the feasibility of our method and shows the measurement process works as intended," said PA Hedin, CEO of SensoDetect AB. "Critically, and not a part of the interim analysis, our AI model is already demonstrating strong performance in detecting ASD-specific biomarkers—which will further improve the final results as we incorporate additional local data from Saudi Arabia."
About the Clinical Study
The study evaluates SensoDetect® Diagnostics (SDD), an advanced neurophysiological tool designed to support earlier and more precise ASD screening. By analyzing auditory brainstem responses (ABR), SDD provides objective data to complement traditional behavioral assessments.
Key Study Aspects:
- Conducted in collaboration with leading Saudi medical institutions
- Aims to validate SDD’s effectiveness across diverse populations
- Includes early screening potential already 24 hours after birth
Why This Matters
- Early Diagnosis Gap: Many children with ASD in Saudi Arabia and worldwide face delayed diagnosis due to reliance on subjective behavioral evaluations. Best outcomes for ASD occur with diagnosis before age 3. The SDD offers a faster, more objective approach
- Early intervention demand: best outcomes for ASD occur with diagnosis before age 3
- Saudi Arabia’s Strategic Role: With 12%+ CAGR growth in ASD diagnostics and Vision 2030 healthcare investments, the country is an ideal validation ground
- Global Potential: Successful results could redefine ASD screening worldwide
Leadership Perspectives
"This study marks a pivotal step in revolutionizing ASD diagnostics," added CEO PA Hedin. "Our goal is to enable earlier intervention and better outcomes globally."
Dr. Saleh, principal investigator of the study in Saudi Arabia, noted:
"SDD could set a new global standard for ASD diagnosis. We’re proud to contribute to this transformative research."
Market Opportunity in Saudi Arabia
- 50+ target clinics/hospitals in major cities (Riyadh, Jeddah)
- Government and private sector demand for AI-driven diagnostics
- Telemedicine integration potential under Vision 2030
For further information, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)73-068 64 20
pa.hedin@sensodetect.com
SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of diagnostics, medication, and health. The products are used in both private and public healthcare as a complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.
More info at https://www.sensodetect.com/
